Tuberculosis (TB)
is characterized by mycobacteria-harboring centrally
necrotizing granulomas. The efficacy of anti-TB drugs depends on their
ability to reach the bacteria in the center of these lesions. Therefore,
we developed a mass spectrometry (MS) imaging workflow to evaluate
drug penetration in tissue. We employed a specific mouse model thatin
contrast to regular inbred micestrongly resembles human TB
pathology. Mycobacterium tuberculosis was inactivated in lung sections of these mice by γ-irradiation
using a protocol that was optimized to be compatible with high spatial
resolution MS imaging. Different distributions in necrotic granulomas
could be observed for the anti-TB drugs clofazimine, pyrazinamide,
and rifampicin at a pixel size of 30 μm. Clofazimine, imaged
here for the first time in necrotic granulomas of mice, showed higher
intensities in the surrounding tissue than in necrotic granulomas,
confirming data observed in TB patients. Using high spatial resolution
drug and lipid imaging (5 μm pixel size) in combination with
a newly developed data analysis tool, we found that clofazimine does
penetrate to some extent into necrotic granulomas and accumulates
in the macrophages inside the granulomas. These results demonstrate
that our imaging platform improves the predictive power of preclinical
animal models. Our workflow is currently being applied in preclinical
studies for novel anti-TB drugs within the German Center for Infection
Research (DZIF). It can also be extended to other applications in
drug development and beyond. In particular, our data analysis approach
can be used to investigate diffusion processes by MS imaging in general.